Mytogen, Inc.
🇺🇸United States
Study to Assess the Efficacy and Safety of Transplanting Autologous Skeletal Myoblasts, Into Infarcted Heart, Using an Catheter Delivery System
Phase 2
- Conditions
- Ischemic Cardiomyopathy
- Interventions
- Biological: myoblastBiological: sham
- First Posted Date
- 2008-02-29
- Last Posted Date
- 2008-02-29
- Lead Sponsor
- Mytogen, Inc.
- Target Recruit Count
- 165
- Registration Number
- NCT00626314
- Locations
- 🇺🇸
Mercy Gilbert, Gilbert, Arizona, United States
© Copyright 2025. All Rights Reserved by MedPath